Showing 1 - 5 results of 5 for search 'Peter Browett', query time: 0.03s Refine Results
  1. 1
    Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria

    Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria by Antonio M. Risitano, Austin G. Kulasekararaj, Jong Wook Lee, Jaroslaw P. Maciejewski, Rosario Notaro, Robert Brodsky, Mingjun Huang, Michael Geffner, Peter Browett

    Published 2020-10-01
    Get full text
    Article
  2. 2
    P675: IMATINIB THERAPY IN PREVIOUSLY UNTREATED CHRONIC MYELOID LEUKAEMIA PATIENTS WHO ACHIEVE MMR AFTER 12 MONTHS THERAPY WITH DASATINIB: A STRATEGY TO AVOID LONG TERM OFF TARGET TOXICITY

    P675: IMATINIB THERAPY IN PREVIOUSLY UNTREATED CHRONIC MYELOID LEUKAEMIA PATIENTS WHO ACHIEVE MMR AFTER 12 MONTHS THERAPY WITH DASATINIB: A STRATEGY TO AVOID LONG TERM OFF TARGET T... by Lucy Pemberton, Katrina Sharples, Yujin Kim, Emma-Jane Mcdonald, Humphrey Pullon, Bart Baker, Merit Hanna, Gordon Royle, Shahidul Islam, Victoria Campion, Michael Findlay, Peter Browett

    Published 2023-08-01
    Get full text
    Article
  3. 3
    High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results

    High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term res... by Angelo Michele Carella, Monica Bellei, Pauline Brice, Christian Gisselbrecht, Giuseppe Visani, Philippe Colombat, Francesco Fabbiano, Amedea Donelli, Stefano Luminari, Pierre Feugier, Peter Browett, Hans Hagberg, Massimo Federico

    Published 2009-01-01
    Get full text
    Article
  4. 4
    Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

    Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemi... by Harry Iland, Ken Bradstock, John Seymour, Mark Hertzberg, Andrew Grigg, Kerry Taylor, John Catalano, Paul Cannell, Noemi Horvath, Sandra Deveridge, Peter Browett, Tim Brighton, Li Chong, Francisca Springall, Juliet Ayling, Alberto Catalano, Shane Supple, Marnie Collins, Juliana Di Iulio, John Reynolds

    Published 2012-02-01
    Get full text
    Article
  5. 5
    P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL

    P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-... by Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim Linton, Pam Mckay, Sophie Leitch, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Peter Browett, Catherine Thieblemont, Anna Marina Liberati, Emmanuel Bachy, Federica Cavallo, Régis Costello, Sunil Iyengar, Roberto Marasca, Heidi Mociková, Jin Seok Kim, Dipti Talaulikar, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co, Judith Trotman

    Published 2023-08-01
    Get full text
    Article

Search Tools: